Kaposi sarcoma-associated herpes virus (KSHV)/Human Herpesvirus 8 (HHV-8)-associated multicentric Castleman disease (MCD) is an inflammatory lymphoproliferative disorder mainly affecting immunocompromised hosts. Gold-standard diagnosis of KSHV/HHV-8 MCD currently relies on lymph node biopsy showing plasma-cell or mixed type Castleman disease associated to the pathognomonic presence of KSHV/HHV-8-infected cells located in the mantle zone. Hemophagocytic lympho-histiocytosis can complicate KSHV/HHV-8 MCD and lead to multiple organ failure and coagulopathy, delaying invasive sampling procedures. Our group previously reported the detection of circulating KSHV/HHV-8-infected cells (called KSHV/HHV-8-infected viroblasts, or KIVs) using standard flow cytometry in a small series of patients with KSHV/HHV-8-MCD flare. These cells had the same phenotype as those described in lymph node, were IgM, lambda and CD38 positive, and CD20 and CD24 negative. While specificity was high (100%) in this preliminary study, flow cytometry lacked sensitivity. The Flow-FISH technique, combining fluorescence in situ hybridization and flow cytometry, offers the advantage of viral transcripts direct and could improve the detection and characterization of KIVs during KSHV/HHV-8 MCD flares. Flow-FISH targeting Latent Nuclear Antigen (LNA) transcript of KSHV/HHV-8 was performed on peripheral blood mononuclear cells (PBMC) obtained from a large cohort of patients with KSHV/HHV-8 MCD flares and compared to standard flow cytometry.

Fifty patients with KSHV/HHV-8 MCD flare were included in the study. All had histological confirmation of KSHV/HHV-8 MCD. Forty (80%) were male with a median age of 54. Thirty-two (64%) had a history of KSHV/HHV-8 MCD before the present flare, and 27 (54%) were living with HIV. Fifteen (30%) had a history of KS and none had history of PEL. Median C-reactive protein (CRP) levels and KSHV/HHV-8 whole blood viral load were 92 mg/L and 5.9 log copies/mL, respectively. Standard multiparametric flow cytometry was performed on PBMC in all patients. This technique was able to detect KIV, previously described as IgM+CD38highCD24-lambda+ cells, in 31 (62%) patients with KSHV/HHV-8 MCD flare (flow-cytometry positive group, or FC+). The percentage of IgM+CD38highCD24-lambda+ cells varied from 0.01% to 9.23% (median at 0.29%) among the CD3-CD14- population. Further extracellular characterization showed variable expression of CD19, CD20, CD27 and CD86 antigens. Flow-FISH was performed in 13 individuals in the FC+ group and showed the presence of LNA transcripts in all patients with LNA+ cells varying from 0.20% to 9% (median at 0.98%) of the CD3-CD14- population. All infected cells had a KIV phenotype and no other infected population was detected. Flow-FISH was performed on 11 samples from the 19 patients with KSHV/HHV-8-MCD flare but without detectable IgM+CD38highCD24-lambda+ population (FC- group). We were able to detect a significant LNA+ population in six additional cases (6/11, 54%, FC-FF+) with LNA+ cells varying from 0.01% to 0.1% (median at 0.04%) of the CD3-CD14- population. Once again, all infected cells had a KIV phenotype and no other infected population was detected. Two patients from the FC-FF- group received corticosteroids and/or etoposide before sampling. Overall, among the 42 patients for whom both standard flow cytometry and Flow-FISH could be performed, 37 (88%) had a detectable KIV population, supporting a role of Flow-FISH in enhancing sensitivity to detect these cells.

We then compared the 31 patients from the FC+ group to the 19 patients from the FC- group. CRP level was significantly higher in the FC+ group (median at 108 mg/L vs 60 mg/L, p=0.03), as well as KSHV/HHV-8 DNA viral load (median at 6.3 copies/mL vs 5.2 copies/mL, p=0.012). The platelet count was significantly lower in the FC+ group (79 G/L vs 200 G/L, p=0.004). Combination of flow cytometry and Flow-FISH had a sensitivity of 88% to diagnose KSHV/HHV-8 MCD flare. Combination of flow cytometry and Flow-FISH emerges as a rapid and sensitive tool when suspecting KSHV/HHV-8 MCD flare, that might help the clinician to start an appropriate and urgent treatment without waiting for the result of lymph node biopsy that will further confirm the diagnosis.

Disclosures

Galicier:Eusapharma: Honoraria. Oksenhendler:Eusapharma: Honoraria.

This content is only available as a PDF.
Sign in via your Institution